Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Author:

Qin Shukui,Chan Stephen L,Gu Shanzhi,Bai Yuxian,Ren Zhenggang,Lin Xiaoyan,Chen Zhendong,Jia Weidong,Jin Yongdong,Guo Yabing,Hu Xiaohua,Meng Zhiqiang,Liang Jun,Cheng Ying,Xiong Jianping,Ren Hong,Yang Fang,Li Wei,Chen Yajin,Zeng Yong,Sultanbaev Alexander,Pazgan-Simon Monika,Pisetska Margaryta,Melisi Davide,Ponomarenko Dmitriy,Osypchuk Yurii,Sinielnikov Ivan,Yang Tsai-Sheng,Liang Xiao,Chen Chunxia,Wang Linna,Cheng Ann-Lii,Kaseb Ahmed,Vogel Arndt,Qin Shukui,Chan Stephen L,Cheng Ann-Lii,Kaseb Ahmed,Vogel Arndt,Gu Shanzhi,Bai Yuxian,Ren Zhenggang,Lin Xiaoyan,Chen Zhendong,Jia Weidong,Jin Yongdong,Guo Yabing,Hu Xiaohua,Meng Zhiqiang,Liang Jun,Cheng Ying,Xiong Jianping,Ren Hong,Yang Fang,Li Wei,Chen Yajin,Zeng Yong,Sultanbaev Alexander,Pazgan-Simon Monika,Pisetska Margaryta,Melisi Davide,Ponomarenko Dmitriy,Osypchuk Yurii,Sinielnikov Ivan,Yang Tsai-Sheng,Liang Xiao,Chen Chunxia,Wang Linna,Zhang Mingxiang,Xu Li,Yuan Xianglin,Li Da,Ying Jierer,Zhang Jingdong,Zhang Tao,Gu Kangsheng,He Yifu,Hao Ping,Jiang Da,Zhang Shu,Xing Baocai,Zhang Baihong,Wang Dong,Zhai Xiaofeng,Liang Houjie,Cybulska-Stopa Bozena,Dvorkin Mikhail,Stroyakovskiy Daniil,Nechaeva Marina,Yen Chia-Jui,Su Wei-Wen,Chen Yen-Hao,Bondarenko Igor,Yang Lin,Fang Weijia,Gomez-Martin Carlos,Ryu Min-Hee,Kim Han-Sang,Kim Jee-Hyun,Zarubenkov Oleg,Orlova Rashida,Poddubskaya Elena,Fadeeva Natalia,Makarova Yulia,Chao Yee,Hung Chao-Hung,Neffa Maryna,Vynnychenko Oleksandr,Burgoyne Adam,Hao Chunyi,Mohr Raphael U,Diaz-Beveridge Roberto,Feliu-Batlle Jaime,Cubillo-Gracian Antonio,Lee Ann-Shing,Daniele Bruno,Antonuzzo Lorenzo,Sangiovanni Angelo,Gasbarrini Antonio,Scartozzi Mario,Ahn Mi Sun,Oh Sung-Yong,Orlov Sergey,Harputluoglu Hakan,Oksuzoglu Berna,Hsu Chiun,Rau Kun-Ming,Krechkovskyi Oleksandr,Yareshko Vladimir,Xiong Henry,Lee Fa-Chyi,Jiang Yixing,Gabayan Afshin,Crow Mary,Van Steenkiste Christophe,Verset Gontran

Publisher

Elsevier BV

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3